CY1116109T1 - Βελτιωμενα φαρμακευτικα σκευασματα αερολυματος - Google Patents
Βελτιωμενα φαρμακευτικα σκευασματα αερολυματοςInfo
- Publication number
- CY1116109T1 CY1116109T1 CY20151100253T CY151100253T CY1116109T1 CY 1116109 T1 CY1116109 T1 CY 1116109T1 CY 20151100253 T CY20151100253 T CY 20151100253T CY 151100253 T CY151100253 T CY 151100253T CY 1116109 T1 CY1116109 T1 CY 1116109T1
- Authority
- CY
- Cyprus
- Prior art keywords
- previous packages
- micronized
- hfa propellant
- improved previous
- improved
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0918149.6A GB0918149D0 (en) | 2009-10-16 | 2009-10-16 | Improved medicinal aerosol formulation |
| EP10768922.6A EP2488158B1 (en) | 2009-10-16 | 2010-10-15 | Improved medicinal aerosol formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116109T1 true CY1116109T1 (el) | 2017-02-08 |
Family
ID=41462450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100253T CY1116109T1 (el) | 2009-10-16 | 2015-03-13 | Βελτιωμενα φαρμακευτικα σκευασματα αερολυματος |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20120282189A1 (enExample) |
| EP (3) | EP2881108B1 (enExample) |
| JP (6) | JP2013507430A (enExample) |
| CN (1) | CN102665675B (enExample) |
| AU (1) | AU2010305698C9 (enExample) |
| BR (1) | BR112012008983A2 (enExample) |
| CA (1) | CA2776359C (enExample) |
| CL (1) | CL2012000947A1 (enExample) |
| CY (1) | CY1116109T1 (enExample) |
| DK (2) | DK2488158T3 (enExample) |
| ES (2) | ES2973882T3 (enExample) |
| FI (1) | FI2881108T3 (enExample) |
| GB (1) | GB0918149D0 (enExample) |
| HR (2) | HRP20150174T1 (enExample) |
| HU (1) | HUE065583T2 (enExample) |
| IL (1) | IL219161B (enExample) |
| LT (1) | LT2881108T (enExample) |
| MX (1) | MX2012004337A (enExample) |
| NZ (1) | NZ599901A (enExample) |
| PL (2) | PL2488158T3 (enExample) |
| PT (2) | PT2881108T (enExample) |
| RS (2) | RS65391B1 (enExample) |
| SI (2) | SI2881108T1 (enExample) |
| SM (2) | SMT202400119T1 (enExample) |
| WO (1) | WO2011045432A1 (enExample) |
| ZA (1) | ZA201202452B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040101483A1 (en) * | 2001-03-30 | 2004-05-27 | Rudi Muller-Walz | Medical aerosol formulations |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0918149D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| TWI495466B (zh) * | 2010-09-23 | 2015-08-11 | Intech Biopharm Ltd | 用於氣喘之吸入性複方組合物 |
| GB201515310D0 (en) * | 2015-08-27 | 2015-10-14 | Jagotec Ag | Pharmaceutical composition |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2503962A1 (de) | 1975-01-31 | 1976-08-05 | Thomae Gmbh Dr K | Spruehbare mittel in suspensionsform zur anwendung auf der haut |
| FR2420972A1 (fr) | 1978-03-31 | 1979-10-26 | Roussel Uclaf | Application du peroxyde de thenoyle a titre de medicament |
| JPS5529524A (en) | 1978-08-21 | 1980-03-01 | Toyo Aerosol Kogyo Kk | Powdery aerosol composition |
| DE2914181C2 (de) | 1979-04-07 | 1982-06-16 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Verfahren und Vorrichtung zum Trocknen temperaturempfindlicher Güter der Pharma- und Nahrungsmittelindustrie |
| JPS6135815A (ja) | 1984-07-28 | 1986-02-20 | Sanshin Seisakusho:Kk | 上部集液式加圧ろ過機に於ける機体内液の脱液方法及び同装置 |
| FR2666962B1 (fr) | 1990-09-26 | 1996-06-14 | Oreal | Composition antifongique sous forme de spray sec. |
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| ES2159678T3 (es) * | 1991-12-18 | 2001-10-16 | Minnesota Mining & Mfg | Formulaciones de aerosol en suspension. |
| DE4321288A1 (de) | 1993-06-26 | 1995-01-05 | Solvay Fluor & Derivate | Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen |
| US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
| DK0731688T3 (da) | 1993-12-02 | 2003-06-23 | Abbott Lab | Aerosol-lægemiddelformuleringer til anvendelse med CFC-frie drivmidler |
| DE69634865D1 (de) | 1995-04-14 | 2005-07-21 | Smithkline Beecham Corp | Dosierinhalator für Salmeterol |
| JP3707107B2 (ja) | 1995-09-18 | 2005-10-19 | 鈴木油脂工業株式会社 | 薬剤分散液及びその製造方法 |
| US6054488A (en) | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
| US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| JP2001509801A (ja) | 1997-01-30 | 2001-07-24 | アルペンストック・ホールディングス・リミテッド | 組成物 |
| US6461591B1 (en) | 1997-02-05 | 2002-10-08 | Jago Research Ag | Medical aerosol formulations |
| US6086376A (en) | 1998-01-30 | 2000-07-11 | Rtp Pharma Inc. | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| US6585958B1 (en) | 1998-07-24 | 2003-07-01 | Jago Research Ag | Medicinal aerosol formulations |
| DK1102579T3 (da) * | 1998-08-04 | 2003-07-14 | Jago Res Ag | Medicinske aerosolformuleringer |
| US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| RU2221552C2 (ru) | 1998-11-13 | 2004-01-20 | Джаго Рисерч Аг | Сухой порошок для ингаляции |
| US7074388B2 (en) * | 1998-12-10 | 2006-07-11 | Kos Life Science, Inc. | Water stabilized medicinal aerosol formulation |
| US6926911B1 (en) | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
| AU2879100A (en) | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
| GB9903759D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| CN1213732C (zh) | 2000-05-22 | 2005-08-10 | 奇斯药制品公司 | 用于加压计量吸入器的稳定药用溶液制剂 |
| WO2002007672A2 (en) * | 2000-07-19 | 2002-01-31 | Aeropharm Technology, Inc. | A medicinal aerosol formulation |
| EP1311294A2 (en) | 2000-08-04 | 2003-05-21 | Longwood Pharmaceutical Research, Inc. | Formulations of mometasone and a bronchodilator for pulmonary administration |
| PL199420B1 (pl) | 2000-10-09 | 2008-09-30 | 3M Innovative Properties Co | Medyczne preparaty aerozolowe |
| US20040101483A1 (en) * | 2001-03-30 | 2004-05-27 | Rudi Muller-Walz | Medical aerosol formulations |
| US6455028B1 (en) | 2001-04-23 | 2002-09-24 | Pharmascience | Ipratropium formulation for pulmonary inhalation |
| GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
| AR036358A1 (es) | 2001-08-28 | 2004-09-01 | Schering Corp | Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma |
| GB0201400D0 (en) | 2002-01-22 | 2002-03-13 | Glaxo Group Ltd | Novel apparatus and process |
| AU2003222753B2 (en) | 2002-03-01 | 2008-04-17 | Chiesi Farmaceutici S.P.A. | Formoterol superfine formulation |
| GB0207899D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and cielesonide aerosol formulations |
| US7582284B2 (en) | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
| EP1531866A1 (en) * | 2002-08-29 | 2005-05-25 | Cipla Ltd. | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| US20060193610A1 (en) | 2003-07-12 | 2006-08-31 | Jong-Hun Han | Aromatic emitting apparatus for using cigarjack |
| EP1670442A4 (en) | 2003-09-19 | 2011-09-14 | Penwest Pharmaceuticals Co | DOSAGE FORMS WITH DELAYED RELEASE |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0323685D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| EP1811981B1 (en) * | 2004-10-12 | 2008-08-13 | Merck Generics (UK) Limited | Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister |
| GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
| JP2015036045A (ja) * | 2013-08-12 | 2015-02-23 | 株式会社泉技研 | 骨質改善のための超音波音響システム及び超音波音響機器の作動方法 |
-
2009
- 2009-10-16 GB GBGB0918149.6A patent/GB0918149D0/en not_active Ceased
-
2010
- 2010-10-15 EP EP14199881.5A patent/EP2881108B1/en active Active
- 2010-10-15 PT PT141998815T patent/PT2881108T/pt unknown
- 2010-10-15 HR HRP20150174TT patent/HRP20150174T1/hr unknown
- 2010-10-15 CA CA2776359A patent/CA2776359C/en active Active
- 2010-10-15 SM SM20240119T patent/SMT202400119T1/it unknown
- 2010-10-15 CN CN201080046310.7A patent/CN102665675B/zh active Active
- 2010-10-15 RS RS20240366A patent/RS65391B1/sr unknown
- 2010-10-15 EP EP10768922.6A patent/EP2488158B1/en not_active Revoked
- 2010-10-15 EP EP23219752.5A patent/EP4327807A3/en active Pending
- 2010-10-15 DK DK10768922T patent/DK2488158T3/en active
- 2010-10-15 SI SI201032141T patent/SI2881108T1/sl unknown
- 2010-10-15 WO PCT/EP2010/065573 patent/WO2011045432A1/en not_active Ceased
- 2010-10-15 ES ES14199881T patent/ES2973882T3/es active Active
- 2010-10-15 MX MX2012004337A patent/MX2012004337A/es active IP Right Grant
- 2010-10-15 BR BR112012008983A patent/BR112012008983A2/pt not_active Application Discontinuation
- 2010-10-15 ES ES10768922.6T patent/ES2533372T3/es active Active
- 2010-10-15 HU HUE14199881A patent/HUE065583T2/hu unknown
- 2010-10-15 PL PL10768922T patent/PL2488158T3/pl unknown
- 2010-10-15 RS RS20150160A patent/RS53883B1/sr unknown
- 2010-10-15 DK DK14199881.5T patent/DK2881108T3/da active
- 2010-10-15 JP JP2012533650A patent/JP2013507430A/ja active Pending
- 2010-10-15 FI FIEP14199881.5T patent/FI2881108T3/fi active
- 2010-10-15 US US13/503,245 patent/US20120282189A1/en not_active Abandoned
- 2010-10-15 PT PT10768922T patent/PT2488158E/pt unknown
- 2010-10-15 PL PL14199881.5T patent/PL2881108T3/pl unknown
- 2010-10-15 NZ NZ599901A patent/NZ599901A/xx unknown
- 2010-10-15 AU AU2010305698A patent/AU2010305698C9/en active Active
- 2010-10-15 SI SI201030889T patent/SI2488158T1/sl unknown
- 2010-10-15 HR HRP20240402TT patent/HRP20240402T1/hr unknown
- 2010-10-15 LT LTEP14199881.5T patent/LT2881108T/lt unknown
-
2012
- 2012-04-04 ZA ZA2012/02452A patent/ZA201202452B/en unknown
- 2012-04-13 CL CL2012000947A patent/CL2012000947A1/es unknown
- 2012-04-15 IL IL219161A patent/IL219161B/en active IP Right Grant
-
2014
- 2014-05-16 US US14/279,751 patent/US20140314684A1/en not_active Abandoned
-
2015
- 2015-02-26 JP JP2015036045A patent/JP2015129162A/ja active Pending
- 2015-03-06 SM SM201500052T patent/SMT201500052B/xx unknown
- 2015-03-13 CY CY20151100253T patent/CY1116109T1/el unknown
-
2016
- 2016-09-14 US US15/265,467 patent/US10471077B2/en active Active
- 2016-12-27 JP JP2016252909A patent/JP6568511B2/ja active Active
-
2019
- 2019-08-02 JP JP2019142684A patent/JP7203701B2/ja active Active
-
2022
- 2022-12-27 JP JP2022209895A patent/JP2023026517A/ja active Pending
-
2025
- 2025-07-31 JP JP2025127827A patent/JP2025148616A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121843T1 (el) | Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου | |
| CY1125393T1 (el) | Αναστολεις του υποδοχεα αυξητικου παραγοντα ινοβλαστων | |
| ECSP22046340A (es) | FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7 | |
| CY1121233T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) | |
| CY1116109T1 (el) | Βελτιωμενα φαρμακευτικα σκευασματα αερολυματος | |
| CY1119767T1 (el) | Παραγωγα πιπεριδινυλικης ινδολης και η χρηση τους ως αναστολεις του παραγοντα β του συμπληρωματος | |
| NI201800133A (es) | Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| UA112281C2 (uk) | Стабільні інсектицидні композиції і способи їх отримання | |
| EA201190092A1 (ru) | Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me) | |
| TN2018000260A1 (en) | Pharmaceutical composition comprising bispecific antibody constructs. | |
| NI201800132A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| MX2016010675A (es) | Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa). | |
| MY160734A (en) | Besylate salt of a btk inhibitor | |
| MX2010007587A (es) | Compuestos que comprenden un grupo ciclobutoxi. | |
| MY165002A (en) | Cylodextrin complexation methods for formulating peptide proteasome inhibitors | |
| CL2012003104A1 (es) | Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende. | |
| MX339570B (es) | Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio. | |
| BR112014008550A2 (pt) | citramida rasagilina | |
| BR112021022397A2 (pt) | Composição | |
| UA120047C2 (uk) | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) | |
| MX2015007745A (es) | Metodo para activar la celula t auxiliar. | |
| EP4410374A3 (en) | Cylodextrin complexation methods for formulating peptide proteasome inhibitors | |
| UA108858C2 (xx) | Похідні ізоксалідину | |
| BR112013007514A2 (pt) | anticorpo isolado, uso da composição e método | |
| CO2019011547A2 (es) | Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol |